nitroso

• ChemBase ID: 318
• Molecular Formular: NO
• Molecular Mass: 30.0061
• Monoisotopic Mass: 29.99798863
• SMILES: O=[N]
• Canonical SMILES: [N]=O
• InChI: InChI=1S/NO/c1-2
• InChIKey: MWUXSHHQAYIFBG-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: nitroso
• IUPAC Systematic name: Oxidonitrogen(?) (additive)
• IUPAC Traditional name: nitric oxide
• Brand Name: Amidogen, oxo-; INOmax; Mononitrogen monoxide; NMO; NO; Nitric oxide 10% by volume or more; Nitric oxide trimer; Nitrogen monooxide; Nitrogen monoxide; Nitrogen oxide; Nitrosyl radical; RCRA waste number P076; nitrogen protoxide
• Synonyms: Nitric Oxide; Nitric oxide; Nitrogen monoxide; Nitrogen(II) oxide; 氧化氮; 一氧化氮

Database IDs

• CAS Number: 10102-43-9
• EC Number: 233-271-0
• MDL Number: MFCD00011525
• PubChem SID: 24857795; 160963781; 46506897
• PubChem CID: 145068
• CHEBI ID: 16480
• ATC CODE: R07AX01
• CHEMBL: 1200689
• Chemspider ID: 127983
• DrugBank ID: DB00435
• Gmelin ID: 451
• KEGG ID: D00074
• Unique Ingredient Identifier: 31C4KY9ESH
• Wikipedia Title: Nitric_oxide

CALCULATED PROPERTIES

• H Acceptors: 1
• H Donor: 0
• LogD (pH = 5.5): -0.3514
• LogD (pH = 7.4): -0.3514
• Log P: -0.3514
• Molar Refractivity: 2.8858 cm^3
• Polarizability: 1.69344 Å^3
• Polar Surface Area: 34.14 Å^2
• Rotatable Bonds: 0
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: 74 cm^3 dm^-3 in water; 9.49E+004 mg/L
• Apperance: Colourless gas
• Melting Point: -163.6 °C(lit.); -164°C
• Boiling Point: -151.7 °C(lit.); -152°C
• Density: 1.3402 g dm^-3
• Refractive Index: 1.0002697
• Vapor Density: 1.05 (vs air)
• Hydrophobicity(logP): 0
• Std enthalpy of formation: 90.29 kJ mol^-1
• Std molar entropy: 210.76 J K^-1 mol^-1

Safety Information

• RTECS: QX0525000
• European Hazard Symbols: Oxidising (O); Toxic (T)
• UN Number: 1660
• German water hazard class: 1
• Hazard Class: 2.3
• Risk Statements: 8-23-34-44; R8, R23, R34, R44
• Safety Statements: 17-23-36/37/39-45; S1, S17, S23, S36/37/39, S45
• GHS Pictograms: GHS03; GHS05; GHS06
• GHS Signal Word: Danger
• NFPA704:
  

  0

  3

  3

  OX
• GHS Hazard statements: H270-H314-H331
• GHS Precautionary statements: P220-P261-P280-P305 + P351 + P338-P310
• Personal Protective Equipment: Faceshields, Gloves, Goggles, half-mask respirator (US), multi-purpose combination respirator cartridge (US)
• RID/ADR: UN 1660 2.3

Pharmacology Properties

• Admin Routes: Inhalation
• Bioavailability: good
• Half Life: 2–6 seconds
• Metabolism: via pulmonary capillary bed

Product Information

• Purity: 98.5%
• Linear Formula: NO

DETAILS

DrugBank - DB00435

• Drug Groups: approved
• Description: Nitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO. This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. It is also a toxic air pollutant produced by automobile engines and power plants.; ; Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant.; ; The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.
• Indication: For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure
• Pharmacology: Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, Nitric oxide improves oxygenation (as indicated by significant increases in PaO2). Nitric oxide appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better entilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.
• Affected Organisms: Humans and other mammals
• Biotransformation: via pulmonary capillary bed
• Absorption: Nitric oxide is absorbed systemically after inhalation.
• Half Life: 2–6 seconds
• Elimination: Nitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for >70% of the nitric oxide dose inhaled.
• References: Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

Sigma Aldrich - 295566

Packaging
17 L in steel cylinder
Recommended products
Stainless steel control valves Z146951, Z187224 or either of stainless steel regulators Z148504 and Z148512 and a "T"-purge valve Z151661 is recommended.

REFERENCES

• Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. Pubmed